Drug Profile


Alternative Names: SAR-245408; XL-147

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Exelixis; Sanofi
  • Class Antineoplastics; Quinoxalines; Small molecules; Sulfonamides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Glioblastoma; Lymphoma; Non-small cell lung cancer; Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 01 Nov 2014 Sanofi completes a phase I trial in Solid tumours (Monotherapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Japan (NCT01392924)
  • 31 May 2014 Sanofi and Merrimack Pharmaceuticals complete a phase Ib trial in Solid tumours (combination therapy, late-stage disease) in USA (NCT01436565)
  • 01 Oct 2013 Phase-I clinical trials in Lymphoma (second-line therapy or greater; late stage disease) in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top